New Delhi, Jan. 28 -- Pharma major Cipla Ltd on Tuesday posted its highest-ever quarterly revenue and Ebitda margin, as robust sales in India, Europe and emerging markets outweighed weakness in its US business.

Cipla expects to end the ongoing fiscal year exceeding its margin guidance, managing director and global CEO Umang Vohra said, as the Mumbai-based drugmaker beat estimates for revenue and profit for the third quarter ended December.

Ebitda stands for earnings before interest, taxes, depreciation, and amortization, and is a key measure of profitability.

The company reported an Ebitda margin of 28.1% in the quarter ended December, up from 26.3% a year ago, which Vohra said was on the back of a seasonally-strong quarter, with highe...